Introducing targeted therapy to antagonize the GIPR on GIPR-expressing somatotroph adenomas could represent a novel treatment approach for acromegaly patients with a paradoxical GH response pattern to OGTT [46]. The gene discussed is GIPR; the disease is acromegaly.